NCT07054242 2025-10-01A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)Yantai Yuhuangding HospitalPhase 2 Not yet recruiting52 enrolled